



Paul R. LePage, Governor Mary C. Maybew, Commissioner

Department of Health and Human Services
 MaineCare Services
 Pharmacy Unit
 11 State House Station
 Augusta, Maine 04333-0011
 Toll Free (866) 796-2463; Fax: (207) 287-8601
 TTY Users: Dial 711 (Maine Relay)

TO: Maine Drug Utilization Review Board
DATE: October 24, 2016
RE: Maine DUR Board **Meeting** minutes from October 11, 2016

ATTENDANCE	PRESENT	ABSENT	EXCUSED
Linda Glass, MD	X		
Lisa Wendler, Pharm. D., Clinical Pharmacy Specialist, Maine Medical CTR			X
Mike Antonello, MD	X		
Kathleen Polonchek, MD	X		
Kenneth McCall, PharmD	X		
Steve Diaz, MD	X		
Non –Voting			
Mike Ouellette, R.Ph., Change Healthcare	X		
Jeffrey S. Barkin MD, DFAPA	X		
Jacquelyn Hedlund, MD, Change Healthcare	X		
Jan Yorks-Wright, Pharmacy Supervisor, OMS	X		
Roger Bondeson, Director of Operations, OMS	X		
Christopher Pezzullo, State Health Officer DHHS, DO	X		

Guests of the Board: Ed Bosshart, PharmD, Carla Quinlivan, Beth Glidden

CALL TO ORDER: 12PM

Dr. Pezzullo called the meeting to order at 12:00 PM.

PUBLIC COMMENTS

Francis Lobu from BMS: Highlighted the attributes of Eliquis.
 Lance Nicholls from Pfizer: Highlighted the attributes of Eliquis, Genotropin, Xeljanz and Xeljanz XR.
 Amy Tomasello from Mylan: Highlighted the attributes of Epipen.
 Marc Vincent from Merck: Highlighted the attributes of Zepatier.
 Jerod Downing from Purdue Pharm: Highlighted the attributes of Hysingla ER.
 Michael Nelson from Sunovion: Highlighted the attributes of Latuda and Aptiom.
 Douglas Jorgenson, DO from New England Sports and Spine: Spoke of behalf of Hysingla ER.
 Brian Calamari form Abbvie: Highlighted the attributes of Humira and Viekria Pak XR.
 Heidi Beiden from Tris: Highlighted the attributes of Dyananvel XR.

Shaffee Baccttus from J&J: Highlighted the attributes of Invokana, Invega Triz and Prezcobix Trinz.

Evana Robbani from Novo: Highlighted the attributes of Tresiba and Victoza.

Margaret Fisher from Novo: Highlighted the attributes of Novo Eight.

Tom Algozzine from Novartis: Highlighted the attributes of Entresto and Cosentyx.

Contessa Fincher from Teva: Highlighted the attributes of Copaxone 40mg and Cinqair.

OLD BUSINESS

DUR MINUTES

The September DUR meeting minutes were accepted as printed

MAINECARE UPDATE

Roger Bondeson stated that currently the state has a survey out to the pharmacies regarding acquisition cost.

NEW BUSINESS

PRESENT COMPLETED RETRO-DUR SCHEDULE 2017

Change Healthcare presented a schedule for retro-DUR initiatives for 2017. After review by the DUR board because the board will be meeting in December 2016 the first meeting in 2017 will be held on March 14, 2017. All topics outlined were accepted.

Board Decision: No action required

PRESENT RESULTS - DIABETES – APPROPRIATE UTILIZATION OF ANGIOTENSIN MODULATORS IN PATIENTS WITH DIABETES AND HYPERTENSION

Dr. Hedlund presented the additional data on the appropriate utilization of angiotensin modulators in patients with diabetes and hypertension. Since this analysis it was found that it is difficult to ascribe a prescriber who may have a role to play in the potential gap in care (since we do not have a primary care provider identified), and since there was a potentially large cohort of members with a potential gap in care, it seems that a fairly global educational effort would be most viable.

Board Decision: No formal action required

NEW DRUG REVIEWS

Changes made during the voting are listed here and are reflected in the vote.

Suprax chewable to preferred with the tablets non-preferred.

Abilify Tab to non-preferred with the generic Aripiprazole Tab to preferred with tablet splitting.

Latuda Tab to preferred with a step.

Verify that the Humira Pen is included in the offer, bring back to December's meeting.

Category	Drug Name	PDL Status	VOTE	Comments
ADHD AGENTS	APTENSIO XR	NP	All in favor	Offer valid if Adderall XR is listed in non preferred position but preferred over its generic equivalents and is non preferred to Vyvanse
	ADDERALL XR	NP		
	ADZENYS XR	NP		
	DEXTROAMPHETAMINE	NP		
	FOCALIN TAB	NP		
	FOCALIN XR CAP	P		
	METHYLPHENIDATE ER (NON AB)	NP		
	METHYLPHENIDATE ER	NP		
	PROCENTRA	NP		
	RITALIN LA	NP		
	STRATTERA	P		
	QUILLIVANT XR SUS	P		
	VYVANSE CAP	P		
	EVEKEO	NP		
	ZENZEDI	NP		
	QUILICHEW ER	P		
DYANAVAL XR	NP			
AHF VIII	HEMOFIL M VIAL	P	All in favor	
	KOATE-DVI VIAL	P		
	KOVALTRY VIAL	NP		
	MONOCLATE-P	P		
	NOVOEIGHT VIAL	P		
	NUWIQ VIAL	NP		
	RECOMBINATE VIAL	NP		
ALLERGEN IMMUNOTHERAPY	GRASTEK SUB	NP	All in favor	
	RAGWITEK SUB	NP		
ANTIBIOTICS, INHALED FOR CF	BETHKIS	NP	All in favor	
	KITABIS PAK	P		
	TOBI PODHALER	NP		
ANALGESIC, NSAIDS	FLECTOR PATCH	NP	All in favor	

ANALGESICS, OPIOID	BUTRANS DIS	P	All in favor	
	EMBEDA	P		
	IBUDONE TAB	NP		
	HYSINGLA ER	NP		
	KADIAN	NP		
	OXYCONTIN TAB	NP		
ANALGESICS, OPIOID ABUSE	BUNAVAIL	NP	All in favor	
	SUBOXONE SUB	P		
	VIVITROL INJ	P		
	ZUBSOLV	NP		
ANDROGENS/ANABOLICS	ANDROGEL GEL	P	All in favor	
	ANDROGEL PUMP	P		
ANGIOTENSIN MOD-NEPRILYSIN INHIB	ENTRESTO	P	All in favor	
ANTIANGINAL AGENTS	RANEXA	P	All in favor	
ANTIASTHMATIC - BETA - ADRENERGICS	ARCAPTA	NP	All in favor	
	SEREVENT	P		
	STRIVERDI	NP		
ANTIBIOTICS-CEPHALOSPORINS	SUPRAX TAB	NP	All in favor	
	SUPRAX CHEWABLE	P		
ANTICOAGULANTS	ARIXTRA	NP	All in favor	
	ELIQUIS TAB	P		
	FONDAPARINUX	P		
	LOVENOX INJ	NP		
	PRADAXA CAP	P		
	SAVAYSA	NP		
	XARELTO TAB	P		
	ANTICONVULSANTS	DIASTAT GEL		P
FELBATOL		NP		
FYCOMPA TAB		P		
LYRICA CAP		NP		
VIMPAT		P		
TROKENDI XR		NP		
OXTELLAR XR		NP		
APTIOM		NP		
ANTIDEMENTIA AGENTS	EXELON	P	All in favor	
	MEMANTINE	P		
	NAMENDA	NP		
	NAMENDA XR	NP		

	NAMZARIC	NP		
ANTIDEPRESSANTS	VIIBRYD	NP	All in favor	
ANTIDIABETICS-INSULIN	HUMALOG KWIKPEN	NP	All in favor	
	HUMULIN N U-100 PEN	NP		
	HUMULIN 70/30 PEN	NP		
	HUMULIN 75/25 KWIKPEN	NP		
	HUMALOG MIX 50/50 KIWKPEN	NP		
	HUMULIN 75/25 KWIK PEN	NP		
	HUMULIN N KWIKPEN	P		
	HUMULIN R U-500 KWIKPEN	P		
	LANTUS SOLOSTAR PEN	P		
	LEVEMIR FLEXTOUCH PEN	P		
	TRESIBA FLEXTOUCH	NP		
ANTIDIABETIC- NON-INSULIN	BYETTA	P	All in favor	Listed on PDL as preferred Automated lookback for use of either metformin or a metformin combination agent accepted Any other preferred DPP-IV must have the same or greater step-edit as JANUVIA or JANUMET
	GLYXAMBI	NP		
	INVOKAMET TAB	NP		
	INVOKANA	NP		
	JANUMET TAB	P		
	JANUMET XR TAB	P		
	JANUVIA TAB	P		
	JARDIANCE	NP		
	JENTADUETO TAB	P		
	TANZEUM INJ	NP		
	TRADJENTA	P		
	VICTOZA INJ	P		
	SYNJARDY	NP		
ANTIHYPERTENSIVES	PRALUENT	NP	All in favor	
	TRICOR	NP		
	TRILPIX	NP		
	REPATHA	NP		
ANTIHYPERTENSIVE, ARBS	DIOVAN TAB	NP	All in favor	
	DIOVAN HCT TAB	NP		
	VALSARTAN	P		

ANTIHYPERTENSIVE, ACE	EPANED	NP	All in favor	
ANTIHYPERTENSIVE, ARBS/CCB COMBO	AMLODIPINE/VALSARTAN EXFORGE TAB EXFORGE HCT TAB	P NP P	All in favor	
ANTIPSYCHOTICS	ABILIFY MAIN INJ ABILIFY TAB ARIPIPRAZOLE INVEGA SUSTENNA LATUDA TAB SAPHRIS TAB VRAYLAR ARISTADA	NP NP P NP P NP NP NP	All in favor	ARIPIPRAZOLE WILL CONTINUE TO HAVE TABLET SPLITTING LATUDA WILL BE PREFERRED WITH A STEP
ANTIVIRALS, ANTIRETROVIRALS	EVOTAZ TAB NORVIR TAB PREZCOBIX GENVOYA DESCOVY ODEFSEY	P P NP P P NP	All in favor	
ANTIVIRALS, HEPATITIS AGENTS	DAKLINZA TAB RIBAPAK RIBASPHERE HARVONI TAB SOVALDI TAB TECHNIVIE TAB VIEKIRA PAK VIEKIRA XR ZEPATIER	NP NP P P P P P P P	All in favor	Clinical PA Clinical PA Clinical PA Clinical PA Clinical PA Clinical PA
BONE DENSITY REGULATORS	BINOSTO	NP	All in favor	
BIOLOGIC IMMUNOMODULATORS	COSENTYX CIMZIA ENBREL INJ ENBREL SURECLICK HUMIRA HUMIRA PEN SIMPONI STELARA XELJANZ TAB	P NP P P P NP NP NP NP	All in favor	Cosentyx- Preferred position with Step Edit allowing trial and failure of one preferred agent

	XELJANZ XR	NP		Humira- Must fail at least 2 preferred products before authorization for non-preferred product.
BRONCHODIL, ANTICHOLINERGICS	INCRUSE ELPT SPIRIVA HANIHALER CAP SPIRIVA RESPINAT	NP P NP	All in favor	
BRONCHODIL, STEROID INHALANTS	AEROSPAN ASMANEX HFA FLOVENT HFA FLOVENT DISK	P NP P P	All in favor	
BRONCHODIL, SYMPATHOMIMETICS	ADVAIR DISKUS ADVAIR HFA ARNUITY ELIPTA ANORO ELLIPTA BREQ ELLIPTA COMBIVANT RESPIMAT DULERA STIOLTO RESIMAT	NP P NP NP NP NP P NP	All in favor	
DERM, CORTICOSTEROIDS	TEXACORT	P	All in favor	
DERM, SCABICIDES/PEDICULOCIDES	NATROBA SKLICE	P NP	All in favor	
DERM- ANTIPSORIATICS	TALTZ	NP	All in favor	
DERM- ACNE PRODUCTS	BENZOYL PEROXIDE	NP	All in favor	
DIGESTIVE ENZYMES	CREON CAP PERTZYE CAP ULTRESA CAP VIOKACE TAB ZENPEP CAP	P NP NP NP P	All in favor	
ANAPHYLACTIC DEVICES	EPIPEN EPIPEN JR. EPINEPHRINE	P P P	All in favor	

FIBROMYALGIA AGENTS	SAVELLA TAB	NP	All in favor	
GI- ANTIDIARRHEALS	RESTORA	NP	All in favor	
	RESTORA RX	NP		
	RESTORA SPRINKLES	NP		
GI- ANTIEMETICS	DICLEGIS	NP	All in favor	
GI-BOWEL EVACUANT COMBINATIONS	PREPOPIK	NP	All in favor	
GI- ULCERATIVE COLITIS AGENTS	APRISO	P	All in favor	
	CANASA	P		
	LIALDA	NP		
	PENTASA 250MG	P		
GOUT AGENTS	MITIGARE	P	All in favor	
GROWTH HORMORE	GENOTROPIN	P	All in favor	
	NORDITROPIN FLEXPRO	P		
	NUTROPIN AQ	NP		
HEMATAPOIETIC, GROWTH FACTOR	ARANESP	NP	All in favor	
IBS AGENTS	MOVANTIK	NP	All in favor	
	LINZESS CAP	NP		
	VIBERZI	NP		
IVIG	GAMMAPLEX INJ	NP	All in favor	No restrictions
MIGRAINE PRODUCTS	RELPAK TAB	P	All in favor	Dosing limits apply
MULTIVITAMINS, PRENATAL	CITRANATAL ASSURE	NP	All in favor	
	CITRANATAL B -CALM TAB	NP		
	CITRANATAL DHA	NP		
	CITRANATAL 90 DHA	NP		
	CITRANATAL HARMONY CAP	NP		
	CITRANATAL RX TAB	NP		
	CONCEPT OB	NP		
	CONCEPT DHA	NP		
	VITAFOL ULTRA	NP		

VITAFOL- NANO VITAFOL FE+				
MS AGENTS	AUBAGIO TAB BETASERON INJ COPAXONE 20MG GILENYA CAP PLEGRIDY TECFIDERA	P P P P NP NP	All in favor	Clinical PA is required to establish diagnosis and medical necessity.
OP. ADRENERGIC	ALPHAGAN-P SIMBRINZA SUS	NP P	All in favor	
OP. BETA – BLOCKERS	COMBIGAN	P	All in favor	
OPHTHALMIC ANTIALLERGICS	PATADAY PATANOL PAZEO	NP NP P	All in favor	
OPHTHALMIC ANTIBIOTIC- ATINFLAM	TOBRADEX OINT TOBRADEX ST DROPS SUSP TOBRADEX DROPS SUSP	P P NP	All in favor	
OPHTHALMIC ANTIBOTIC	MOXEZA	P	All in favor	
OP. PROSTAGLANDINs	TRAVOPROST	NP	All in favor	
OP. ANTI-INFLAMMATORIES	DUREZOL ILEVRO	P NP	All in favor	
OTIC ANTI-INFECTIVES	CIPRODEX	P	All in favor	
OPHTHALMIC MISC	XIIDRA	NP	All in favor	
PHOSPHATE BINDERS	FOSRENOL CHW PHOSLYRA SOL RENAGEL VELPHORO CHW	NP P P NP	All in favor	
PROGESTINS	MAKENA	P	All in favor	
VASOPROTECTANTS	ORENITRAM	NP	All in favor	

PLATELET AGGREGATION INHIBITORS	BRILINTA TAB	NP	All in	favor
	EFFIENT TAB	NP		
	ZONTIVITY	NP		
PULMONARY HYPERTENSION-ERAS	LETAIRIS TAB	P	All in	Requires WHO Group 1 diagnosis of primary PAH (Primary Pulmonary Hypertension) and functional class 2 or 3 symptoms.
	OPSUMIT TAB	NP	favor	
	TRACLEER TAB	P		
SEDATIVE HYPNOTICS	BELSOMRA	NP	All in	favor
SMOKING DETERENTS	CHANTIX PAK	NP	All in	favor
	CHANTIX TAB	P		
URINARY ANTISPASMODICS	MYRBETRIQ TAB	NP	All in	favor
	TOVIAZ TAB	P		
VAGINAL ANTI-INFECTIVES	CLINDESSE	P	All in	favor
	GYNAZOLE-1	NP		

Board Decision: The Board unanimously approved the above recommendation.

FDA SAFETY ALERTS

FDA launches competition to spur innovative technologies to help reduce opioid overdose deaths
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm520945.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery

Eye Wash/Eye Irrigating Solutions Distributed by Major Pharmaceuticals and Rugby Laboratories: Recall - Microbial Contamination
http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm519570.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery

Hyoscyamine Sulfate 0.125mg by Virtus Pharmaceuticals: Recall - Superpotent and Subpotent Test Results
http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm520868.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery

Lamotrigine Orally Disintegrating Tablet 200 mg by Impax: Recall - Incorrect Labeling of Blister Cards
http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm518486.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery

Opioid Pain or Cough Medicines Combined With Benzodiazepines: Drug Safety Communication - FDA Requiring Boxed Warning About Serious Risks and Death

http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm518710.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery

Ovarian Cancer Screening Tests: Safety Communication - FDA Recommends Against Use

http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm519540.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery

Direct-Acting Antivirals for Hepatitis C: Drug Safety Communication - Risk of Hepatitis B Reactivating

http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm523690.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery

Board Decision: Due to time restraints the board voted to move the above FDA alerts to the December meeting.

ADJOURNMENT: 4PM

The next meeting will be held on **December 13, 2016** 5:30pm –8:30pm at the Augusta Armory.